Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations
Radiation therapy is a major treatment modality used in > 60% of cancer patients as definitive local treatment for inoperable locoregionally confined tumors and as palliative therapy. Although cytotoxic chemotherapy enhances the effectiveness of treatment, the benefit over radiation therapy alone...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Lin, Steven H. [verfasserIn] Willers, Henning [verfasserIn] Krishnan, Sunil [verfasserIn] Sarkaria, Jann N. [verfasserIn] Baumann, Michael [verfasserIn] Lawrence, Theodore S. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Übergeordnetes Werk: |
Enthalten in: International journal of radiation oncology, biology, physics - Amsterdam [u.a.] : Elsevier Science, 1975, 111, Seite 1131-1139 |
|---|---|
| Übergeordnetes Werk: |
volume:111 ; pages:1131-1139 |
| DOI / URN: |
10.1016/j.ijrobp.2021.08.018 |
|---|
| Katalog-ID: |
ELV006926797 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV006926797 | ||
| 003 | DE-627 | ||
| 005 | 20230524124159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230506s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijrobp.2021.08.018 |2 doi | |
| 035 | |a (DE-627)ELV006926797 | ||
| 035 | |a (ELSEVIER)S0360-3016(21)02706-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 084 | |a 44.64 |2 bkl | ||
| 084 | |a 44.81 |2 bkl | ||
| 100 | 1 | |a Lin, Steven H. |e verfasserin |0 (orcid)0000-0003-4411-0634 |4 aut | |
| 245 | 1 | 0 | |a Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations |
| 264 | 1 | |c 2021 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Radiation therapy is a major treatment modality used in > 60% of cancer patients as definitive local treatment for inoperable locoregionally confined tumors and as palliative therapy. Although cytotoxic chemotherapy enhances the effectiveness of treatment, the benefit over radiation therapy alone is modest. There is a need to enhance the effectiveness of local tumor control over what sequentially or concurrently administered cytotoxic chemotherapy provides. Although many biological pathways are known to enhance the effectiveness of radiation therapy, there is currently a paucity of drugs approved for use in combination. Several clinical trials have tested the effectiveness of combining targeted agents or immunotherapies with radiation therapy, but the results of these trials have been negative, likely stemming from the relative lack of preclinical evidence using appropriate experimental standardization or model systems. Accelerating the identification of agents tested in an appropriate clinical context and experimental systems or models would greatly enhance the potential to bring forward early testing of drugs that would not only be safe but also more effective. This article provides an overview of the opportunities and challenges of developing therapeutics to combine with radiation therapy, and some guidance toward preclinical and early clinical testing to improve the chance that advanced phase testing of drug-radiation combinations would be successful in the long term. | ||
| 700 | 1 | |a Willers, Henning |e verfasserin |4 aut | |
| 700 | 1 | |a Krishnan, Sunil |e verfasserin |4 aut | |
| 700 | 1 | |a Sarkaria, Jann N. |e verfasserin |4 aut | |
| 700 | 1 | |a Baumann, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Lawrence, Theodore S. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of radiation oncology, biology, physics |d Amsterdam [u.a.] : Elsevier Science, 1975 |g 111, Seite 1131-1139 |h Online-Ressource |w (DE-627)306659662 |w (DE-600)1500486-7 |w (DE-576)081986319 |x 1879-355X |7 nnns |
| 773 | 1 | 8 | |g volume:111 |g pages:1131-1139 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_2011 | ||
| 936 | b | k | |a 44.64 |j Radiologie |
| 936 | b | k | |a 44.81 |j Onkologie |
| 951 | |a AR | ||
| 952 | |d 111 |h 1131-1139 | ||
| author_variant |
s h l sh shl h w hw s k sk j n s jn jns m b mb t s l ts tsl |
|---|---|
| matchkey_str |
article:1879355X:2021----::oigeodhsadrocraclrttsigfait |
| hierarchy_sort_str |
2021 |
| bklnumber |
44.64 44.81 |
| publishDate |
2021 |
| allfields |
10.1016/j.ijrobp.2021.08.018 doi (DE-627)ELV006926797 (ELSEVIER)S0360-3016(21)02706-1 DE-627 ger DE-627 rda eng 610 DE-600 44.64 bkl 44.81 bkl Lin, Steven H. verfasserin (orcid)0000-0003-4411-0634 aut Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations 2021 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Radiation therapy is a major treatment modality used in > 60% of cancer patients as definitive local treatment for inoperable locoregionally confined tumors and as palliative therapy. Although cytotoxic chemotherapy enhances the effectiveness of treatment, the benefit over radiation therapy alone is modest. There is a need to enhance the effectiveness of local tumor control over what sequentially or concurrently administered cytotoxic chemotherapy provides. Although many biological pathways are known to enhance the effectiveness of radiation therapy, there is currently a paucity of drugs approved for use in combination. Several clinical trials have tested the effectiveness of combining targeted agents or immunotherapies with radiation therapy, but the results of these trials have been negative, likely stemming from the relative lack of preclinical evidence using appropriate experimental standardization or model systems. Accelerating the identification of agents tested in an appropriate clinical context and experimental systems or models would greatly enhance the potential to bring forward early testing of drugs that would not only be safe but also more effective. This article provides an overview of the opportunities and challenges of developing therapeutics to combine with radiation therapy, and some guidance toward preclinical and early clinical testing to improve the chance that advanced phase testing of drug-radiation combinations would be successful in the long term. Willers, Henning verfasserin aut Krishnan, Sunil verfasserin aut Sarkaria, Jann N. verfasserin aut Baumann, Michael verfasserin aut Lawrence, Theodore S. verfasserin aut Enthalten in International journal of radiation oncology, biology, physics Amsterdam [u.a.] : Elsevier Science, 1975 111, Seite 1131-1139 Online-Ressource (DE-627)306659662 (DE-600)1500486-7 (DE-576)081986319 1879-355X nnns volume:111 pages:1131-1139 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_31 GBV_ILN_2011 44.64 Radiologie 44.81 Onkologie AR 111 1131-1139 |
| spelling |
10.1016/j.ijrobp.2021.08.018 doi (DE-627)ELV006926797 (ELSEVIER)S0360-3016(21)02706-1 DE-627 ger DE-627 rda eng 610 DE-600 44.64 bkl 44.81 bkl Lin, Steven H. verfasserin (orcid)0000-0003-4411-0634 aut Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations 2021 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Radiation therapy is a major treatment modality used in > 60% of cancer patients as definitive local treatment for inoperable locoregionally confined tumors and as palliative therapy. Although cytotoxic chemotherapy enhances the effectiveness of treatment, the benefit over radiation therapy alone is modest. There is a need to enhance the effectiveness of local tumor control over what sequentially or concurrently administered cytotoxic chemotherapy provides. Although many biological pathways are known to enhance the effectiveness of radiation therapy, there is currently a paucity of drugs approved for use in combination. Several clinical trials have tested the effectiveness of combining targeted agents or immunotherapies with radiation therapy, but the results of these trials have been negative, likely stemming from the relative lack of preclinical evidence using appropriate experimental standardization or model systems. Accelerating the identification of agents tested in an appropriate clinical context and experimental systems or models would greatly enhance the potential to bring forward early testing of drugs that would not only be safe but also more effective. This article provides an overview of the opportunities and challenges of developing therapeutics to combine with radiation therapy, and some guidance toward preclinical and early clinical testing to improve the chance that advanced phase testing of drug-radiation combinations would be successful in the long term. Willers, Henning verfasserin aut Krishnan, Sunil verfasserin aut Sarkaria, Jann N. verfasserin aut Baumann, Michael verfasserin aut Lawrence, Theodore S. verfasserin aut Enthalten in International journal of radiation oncology, biology, physics Amsterdam [u.a.] : Elsevier Science, 1975 111, Seite 1131-1139 Online-Ressource (DE-627)306659662 (DE-600)1500486-7 (DE-576)081986319 1879-355X nnns volume:111 pages:1131-1139 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_31 GBV_ILN_2011 44.64 Radiologie 44.81 Onkologie AR 111 1131-1139 |
| allfields_unstemmed |
10.1016/j.ijrobp.2021.08.018 doi (DE-627)ELV006926797 (ELSEVIER)S0360-3016(21)02706-1 DE-627 ger DE-627 rda eng 610 DE-600 44.64 bkl 44.81 bkl Lin, Steven H. verfasserin (orcid)0000-0003-4411-0634 aut Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations 2021 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Radiation therapy is a major treatment modality used in > 60% of cancer patients as definitive local treatment for inoperable locoregionally confined tumors and as palliative therapy. Although cytotoxic chemotherapy enhances the effectiveness of treatment, the benefit over radiation therapy alone is modest. There is a need to enhance the effectiveness of local tumor control over what sequentially or concurrently administered cytotoxic chemotherapy provides. Although many biological pathways are known to enhance the effectiveness of radiation therapy, there is currently a paucity of drugs approved for use in combination. Several clinical trials have tested the effectiveness of combining targeted agents or immunotherapies with radiation therapy, but the results of these trials have been negative, likely stemming from the relative lack of preclinical evidence using appropriate experimental standardization or model systems. Accelerating the identification of agents tested in an appropriate clinical context and experimental systems or models would greatly enhance the potential to bring forward early testing of drugs that would not only be safe but also more effective. This article provides an overview of the opportunities and challenges of developing therapeutics to combine with radiation therapy, and some guidance toward preclinical and early clinical testing to improve the chance that advanced phase testing of drug-radiation combinations would be successful in the long term. Willers, Henning verfasserin aut Krishnan, Sunil verfasserin aut Sarkaria, Jann N. verfasserin aut Baumann, Michael verfasserin aut Lawrence, Theodore S. verfasserin aut Enthalten in International journal of radiation oncology, biology, physics Amsterdam [u.a.] : Elsevier Science, 1975 111, Seite 1131-1139 Online-Ressource (DE-627)306659662 (DE-600)1500486-7 (DE-576)081986319 1879-355X nnns volume:111 pages:1131-1139 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_31 GBV_ILN_2011 44.64 Radiologie 44.81 Onkologie AR 111 1131-1139 |
| allfieldsGer |
10.1016/j.ijrobp.2021.08.018 doi (DE-627)ELV006926797 (ELSEVIER)S0360-3016(21)02706-1 DE-627 ger DE-627 rda eng 610 DE-600 44.64 bkl 44.81 bkl Lin, Steven H. verfasserin (orcid)0000-0003-4411-0634 aut Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations 2021 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Radiation therapy is a major treatment modality used in > 60% of cancer patients as definitive local treatment for inoperable locoregionally confined tumors and as palliative therapy. Although cytotoxic chemotherapy enhances the effectiveness of treatment, the benefit over radiation therapy alone is modest. There is a need to enhance the effectiveness of local tumor control over what sequentially or concurrently administered cytotoxic chemotherapy provides. Although many biological pathways are known to enhance the effectiveness of radiation therapy, there is currently a paucity of drugs approved for use in combination. Several clinical trials have tested the effectiveness of combining targeted agents or immunotherapies with radiation therapy, but the results of these trials have been negative, likely stemming from the relative lack of preclinical evidence using appropriate experimental standardization or model systems. Accelerating the identification of agents tested in an appropriate clinical context and experimental systems or models would greatly enhance the potential to bring forward early testing of drugs that would not only be safe but also more effective. This article provides an overview of the opportunities and challenges of developing therapeutics to combine with radiation therapy, and some guidance toward preclinical and early clinical testing to improve the chance that advanced phase testing of drug-radiation combinations would be successful in the long term. Willers, Henning verfasserin aut Krishnan, Sunil verfasserin aut Sarkaria, Jann N. verfasserin aut Baumann, Michael verfasserin aut Lawrence, Theodore S. verfasserin aut Enthalten in International journal of radiation oncology, biology, physics Amsterdam [u.a.] : Elsevier Science, 1975 111, Seite 1131-1139 Online-Ressource (DE-627)306659662 (DE-600)1500486-7 (DE-576)081986319 1879-355X nnns volume:111 pages:1131-1139 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_31 GBV_ILN_2011 44.64 Radiologie 44.81 Onkologie AR 111 1131-1139 |
| allfieldsSound |
10.1016/j.ijrobp.2021.08.018 doi (DE-627)ELV006926797 (ELSEVIER)S0360-3016(21)02706-1 DE-627 ger DE-627 rda eng 610 DE-600 44.64 bkl 44.81 bkl Lin, Steven H. verfasserin (orcid)0000-0003-4411-0634 aut Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations 2021 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Radiation therapy is a major treatment modality used in > 60% of cancer patients as definitive local treatment for inoperable locoregionally confined tumors and as palliative therapy. Although cytotoxic chemotherapy enhances the effectiveness of treatment, the benefit over radiation therapy alone is modest. There is a need to enhance the effectiveness of local tumor control over what sequentially or concurrently administered cytotoxic chemotherapy provides. Although many biological pathways are known to enhance the effectiveness of radiation therapy, there is currently a paucity of drugs approved for use in combination. Several clinical trials have tested the effectiveness of combining targeted agents or immunotherapies with radiation therapy, but the results of these trials have been negative, likely stemming from the relative lack of preclinical evidence using appropriate experimental standardization or model systems. Accelerating the identification of agents tested in an appropriate clinical context and experimental systems or models would greatly enhance the potential to bring forward early testing of drugs that would not only be safe but also more effective. This article provides an overview of the opportunities and challenges of developing therapeutics to combine with radiation therapy, and some guidance toward preclinical and early clinical testing to improve the chance that advanced phase testing of drug-radiation combinations would be successful in the long term. Willers, Henning verfasserin aut Krishnan, Sunil verfasserin aut Sarkaria, Jann N. verfasserin aut Baumann, Michael verfasserin aut Lawrence, Theodore S. verfasserin aut Enthalten in International journal of radiation oncology, biology, physics Amsterdam [u.a.] : Elsevier Science, 1975 111, Seite 1131-1139 Online-Ressource (DE-627)306659662 (DE-600)1500486-7 (DE-576)081986319 1879-355X nnns volume:111 pages:1131-1139 GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_31 GBV_ILN_2011 44.64 Radiologie 44.81 Onkologie AR 111 1131-1139 |
| language |
English |
| source |
Enthalten in International journal of radiation oncology, biology, physics 111, Seite 1131-1139 volume:111 pages:1131-1139 |
| sourceStr |
Enthalten in International journal of radiation oncology, biology, physics 111, Seite 1131-1139 volume:111 pages:1131-1139 |
| format_phy_str_mv |
Article |
| bklname |
Radiologie Onkologie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
International journal of radiation oncology, biology, physics |
| authorswithroles_txt_mv |
Lin, Steven H. @@aut@@ Willers, Henning @@aut@@ Krishnan, Sunil @@aut@@ Sarkaria, Jann N. @@aut@@ Baumann, Michael @@aut@@ Lawrence, Theodore S. @@aut@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
306659662 |
| dewey-sort |
3610 |
| id |
ELV006926797 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV006926797</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230524124159.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230506s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijrobp.2021.08.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV006926797</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0360-3016(21)02706-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.64</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.81</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lin, Steven H.</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0003-4411-0634</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Radiation therapy is a major treatment modality used in > 60% of cancer patients as definitive local treatment for inoperable locoregionally confined tumors and as palliative therapy. Although cytotoxic chemotherapy enhances the effectiveness of treatment, the benefit over radiation therapy alone is modest. There is a need to enhance the effectiveness of local tumor control over what sequentially or concurrently administered cytotoxic chemotherapy provides. Although many biological pathways are known to enhance the effectiveness of radiation therapy, there is currently a paucity of drugs approved for use in combination. Several clinical trials have tested the effectiveness of combining targeted agents or immunotherapies with radiation therapy, but the results of these trials have been negative, likely stemming from the relative lack of preclinical evidence using appropriate experimental standardization or model systems. Accelerating the identification of agents tested in an appropriate clinical context and experimental systems or models would greatly enhance the potential to bring forward early testing of drugs that would not only be safe but also more effective. This article provides an overview of the opportunities and challenges of developing therapeutics to combine with radiation therapy, and some guidance toward preclinical and early clinical testing to improve the chance that advanced phase testing of drug-radiation combinations would be successful in the long term.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Willers, Henning</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Krishnan, Sunil</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sarkaria, Jann N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Baumann, Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lawrence, Theodore S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">International journal of radiation oncology, biology, physics</subfield><subfield code="d">Amsterdam [u.a.] : Elsevier Science, 1975</subfield><subfield code="g">111, Seite 1131-1139</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)306659662</subfield><subfield code="w">(DE-600)1500486-7</subfield><subfield code="w">(DE-576)081986319</subfield><subfield code="x">1879-355X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:111</subfield><subfield code="g">pages:1131-1139</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.64</subfield><subfield code="j">Radiologie</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.81</subfield><subfield code="j">Onkologie</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">111</subfield><subfield code="h">1131-1139</subfield></datafield></record></collection>
|
| author |
Lin, Steven H. |
| spellingShingle |
Lin, Steven H. ddc 610 bkl 44.64 bkl 44.81 Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations |
| authorStr |
Lin, Steven H. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)306659662 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1879-355X |
| topic_title |
610 DE-600 44.64 bkl 44.81 bkl Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations |
| topic |
ddc 610 bkl 44.64 bkl 44.81 |
| topic_unstemmed |
ddc 610 bkl 44.64 bkl 44.81 |
| topic_browse |
ddc 610 bkl 44.64 bkl 44.81 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
International journal of radiation oncology, biology, physics |
| hierarchy_parent_id |
306659662 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
International journal of radiation oncology, biology, physics |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)306659662 (DE-600)1500486-7 (DE-576)081986319 |
| title |
Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations |
| ctrlnum |
(DE-627)ELV006926797 (ELSEVIER)S0360-3016(21)02706-1 |
| title_full |
Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations |
| author_sort |
Lin, Steven H. |
| journal |
International journal of radiation oncology, biology, physics |
| journalStr |
International journal of radiation oncology, biology, physics |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
zzz |
| container_start_page |
1131 |
| author_browse |
Lin, Steven H. Willers, Henning Krishnan, Sunil Sarkaria, Jann N. Baumann, Michael Lawrence, Theodore S. |
| container_volume |
111 |
| class |
610 DE-600 44.64 bkl 44.81 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Lin, Steven H. |
| doi_str_mv |
10.1016/j.ijrobp.2021.08.018 |
| normlink |
(ORCID)0000-0003-4411-0634 |
| normlink_prefix_str_mv |
(orcid)0000-0003-4411-0634 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
moving beyond the standard of care: accelerate testing of radiation-drug combinations |
| title_auth |
Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations |
| abstract |
Radiation therapy is a major treatment modality used in > 60% of cancer patients as definitive local treatment for inoperable locoregionally confined tumors and as palliative therapy. Although cytotoxic chemotherapy enhances the effectiveness of treatment, the benefit over radiation therapy alone is modest. There is a need to enhance the effectiveness of local tumor control over what sequentially or concurrently administered cytotoxic chemotherapy provides. Although many biological pathways are known to enhance the effectiveness of radiation therapy, there is currently a paucity of drugs approved for use in combination. Several clinical trials have tested the effectiveness of combining targeted agents or immunotherapies with radiation therapy, but the results of these trials have been negative, likely stemming from the relative lack of preclinical evidence using appropriate experimental standardization or model systems. Accelerating the identification of agents tested in an appropriate clinical context and experimental systems or models would greatly enhance the potential to bring forward early testing of drugs that would not only be safe but also more effective. This article provides an overview of the opportunities and challenges of developing therapeutics to combine with radiation therapy, and some guidance toward preclinical and early clinical testing to improve the chance that advanced phase testing of drug-radiation combinations would be successful in the long term. |
| abstractGer |
Radiation therapy is a major treatment modality used in > 60% of cancer patients as definitive local treatment for inoperable locoregionally confined tumors and as palliative therapy. Although cytotoxic chemotherapy enhances the effectiveness of treatment, the benefit over radiation therapy alone is modest. There is a need to enhance the effectiveness of local tumor control over what sequentially or concurrently administered cytotoxic chemotherapy provides. Although many biological pathways are known to enhance the effectiveness of radiation therapy, there is currently a paucity of drugs approved for use in combination. Several clinical trials have tested the effectiveness of combining targeted agents or immunotherapies with radiation therapy, but the results of these trials have been negative, likely stemming from the relative lack of preclinical evidence using appropriate experimental standardization or model systems. Accelerating the identification of agents tested in an appropriate clinical context and experimental systems or models would greatly enhance the potential to bring forward early testing of drugs that would not only be safe but also more effective. This article provides an overview of the opportunities and challenges of developing therapeutics to combine with radiation therapy, and some guidance toward preclinical and early clinical testing to improve the chance that advanced phase testing of drug-radiation combinations would be successful in the long term. |
| abstract_unstemmed |
Radiation therapy is a major treatment modality used in > 60% of cancer patients as definitive local treatment for inoperable locoregionally confined tumors and as palliative therapy. Although cytotoxic chemotherapy enhances the effectiveness of treatment, the benefit over radiation therapy alone is modest. There is a need to enhance the effectiveness of local tumor control over what sequentially or concurrently administered cytotoxic chemotherapy provides. Although many biological pathways are known to enhance the effectiveness of radiation therapy, there is currently a paucity of drugs approved for use in combination. Several clinical trials have tested the effectiveness of combining targeted agents or immunotherapies with radiation therapy, but the results of these trials have been negative, likely stemming from the relative lack of preclinical evidence using appropriate experimental standardization or model systems. Accelerating the identification of agents tested in an appropriate clinical context and experimental systems or models would greatly enhance the potential to bring forward early testing of drugs that would not only be safe but also more effective. This article provides an overview of the opportunities and challenges of developing therapeutics to combine with radiation therapy, and some guidance toward preclinical and early clinical testing to improve the chance that advanced phase testing of drug-radiation combinations would be successful in the long term. |
| collection_details |
GBV_USEFLAG_U SYSFLAG_U GBV_ELV SSG-OLC-PHA GBV_ILN_31 GBV_ILN_2011 |
| title_short |
Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations |
| remote_bool |
true |
| author2 |
Willers, Henning Krishnan, Sunil Sarkaria, Jann N. Baumann, Michael Lawrence, Theodore S. |
| author2Str |
Willers, Henning Krishnan, Sunil Sarkaria, Jann N. Baumann, Michael Lawrence, Theodore S. |
| ppnlink |
306659662 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.ijrobp.2021.08.018 |
| up_date |
2024-07-06T23:01:39.589Z |
| _version_ |
1803872527544483840 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV006926797</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230524124159.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230506s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijrobp.2021.08.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV006926797</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0360-3016(21)02706-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.64</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.81</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lin, Steven H.</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0003-4411-0634</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Radiation therapy is a major treatment modality used in > 60% of cancer patients as definitive local treatment for inoperable locoregionally confined tumors and as palliative therapy. Although cytotoxic chemotherapy enhances the effectiveness of treatment, the benefit over radiation therapy alone is modest. There is a need to enhance the effectiveness of local tumor control over what sequentially or concurrently administered cytotoxic chemotherapy provides. Although many biological pathways are known to enhance the effectiveness of radiation therapy, there is currently a paucity of drugs approved for use in combination. Several clinical trials have tested the effectiveness of combining targeted agents or immunotherapies with radiation therapy, but the results of these trials have been negative, likely stemming from the relative lack of preclinical evidence using appropriate experimental standardization or model systems. Accelerating the identification of agents tested in an appropriate clinical context and experimental systems or models would greatly enhance the potential to bring forward early testing of drugs that would not only be safe but also more effective. This article provides an overview of the opportunities and challenges of developing therapeutics to combine with radiation therapy, and some guidance toward preclinical and early clinical testing to improve the chance that advanced phase testing of drug-radiation combinations would be successful in the long term.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Willers, Henning</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Krishnan, Sunil</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sarkaria, Jann N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Baumann, Michael</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lawrence, Theodore S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">International journal of radiation oncology, biology, physics</subfield><subfield code="d">Amsterdam [u.a.] : Elsevier Science, 1975</subfield><subfield code="g">111, Seite 1131-1139</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)306659662</subfield><subfield code="w">(DE-600)1500486-7</subfield><subfield code="w">(DE-576)081986319</subfield><subfield code="x">1879-355X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:111</subfield><subfield code="g">pages:1131-1139</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.64</subfield><subfield code="j">Radiologie</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.81</subfield><subfield code="j">Onkologie</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">111</subfield><subfield code="h">1131-1139</subfield></datafield></record></collection>
|
| score |
7.397848 |